| Identification | Back Directory | [Name]
hepsulfam | [CAS]
96892-57-8 | [Synonyms]
hepsulfam
NSC-329680
NCI 329680
ZINC01574758
7-sulfamoyloxyheptyl sulfamate
Sulfamic acid, S,S'-1,7-heptanediyl ester
Bissulfamideoic acid 1,7-heptanediyl ester
Bis(amidosulfuric acid)1,7-heptanediyl ester | [Molecular Formula]
C7H18N2O6S2 | [MOL File]
96892-57-8.mol | [Molecular Weight]
290.36 |
| Chemical Properties | Back Directory | [Melting point ]
94-95 °C | [Boiling point ]
478.2±55.0 °C(Predicted) | [density ]
1.407±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
9.10±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Hepsulfam (NCI 329680; ZINC01574758) is a anticancer agent that shows excellent antileukemic activity with an median IC50 of 0.91 μg/mL in a panel of different tumors. | [in vivo]
Hepsulfam demonstrates superior in vivo activity in a large cell lung cancer xenograft and a gastric carcinoma model. The preclinical activity of hepsulfam suggests a possible role of this compound in the treatment of solid human malignancies. However, the increased bone marrow toxicity of hepsulfam as compared with busulfan might be critical for further clinical application[1]. | [References]
[1] Berger DP, et al. Preclinical activity of hepsulfam and busulfan in solid human tumor xenografts and human bone marrow. Anticancer Drugs. 1992 Oct;3(5):531-9. DOI:10.1097/00001813-199210000-00014
[2] Pacheco DY, et al. Mechanisms of toxicity of hepsulfam in human tumor cell lines. Cancer Res. 1990 Dec 1;50(23):7555-8. PMID:2253204 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|